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Context: Insulin autoimmune syndrome (IAS), spontaneous hyperinsulinemic hypoglycemia due to
insulin-binding autoantibodies, may be difficult to distinguish from tumoral or other forms of
hyperinsulinemic hypoglycemia, including surreptitious insulin administration. No standardized
treatment regimen exists.
Objectives: To evaluate an analytic approach to IAS and responses to different treatments.
Design and Setting: Observational study in the UK Severe Insulin Resistance Service.
Patients: Six patients with hyperinsulinemic hypoglycemia and detectable circulating anti–insulin
antibody (IA).
Main OutcomeMeasures: Glycemia, plasma insulin, and C-peptide concentrations by immunoassay
or mass spectrometry (MS). Immunoreactive insulin was determined in the context of polyethylene
glycol (PEG) precipitation and gel filtration chromatography (GFC). IA quantification using ELISA
and RIA, and IA were further characterized using radioligand binding studies.
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Abbreviations: CBG, capillary blood glucose; CGMS, continuous glucose monitoring
system; GFC, gel filtration chromatography; HMW, high molecular weight; IA, anti–
insulin antibody; IAS, insulin autoimmune syndrome; MMF, mycophenolate mofetil; MS,
mass spectrometry; NR, normal range; OGTT, oral glucose tolerance test; PAS, protein A
Sepharose; PEG, polyethylene glycol; PGS, protein G Sepharose.
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Results: All patients were diagnosed with IAS (five IgG, one IgA) based on a high insulin/
C-peptide ratio, low insulin recovery after PEG precipitation, and GFC evidence of antibody-
bound insulin. Neither ELISA nor RIA result proved diagnostic for every case. MS provided amore
robust quantification of insulin in the context of IA. One patient was managed conservatively,
four were treated with diazoxide without sustained benefit, and four were treated with
immunosuppression with highly variable responses. IA affinity did not appear to influence
presentation or prognosis.
Conclusions: IAS should be considered in patients with hyperinsulinemic hypoglycemia and a high
insulin/C-peptide ratio. Low insulin recovery on PEG precipitation supports the presence of insulin-
binding antibodies, with GFC providing definitive confirmation. Immunomodulatory therapy
should be customized according to individual needs and clinical response. (J Clin Endocrinol
Metab 103: 3845–3855, 2018)
Insulin autoimmune syndrome (IAS) features hyper-insulinemic hypoglycemia due to insulin autoanti-
bodies in exogenous insulin-naive individuals (1, 2). IAS
presents with recurrent postabsorptive or fasting hypo-
glycemia, alternating with postprandial hyperglycemia,
due to “buffering” by autoantibodies, which sequester
insulin in immune complexes during the acute phase of
insulin secretion, only to release it slowly later, at physio-
logically inappropriate times.
IAS cannot easily be distinguished on clinical grounds
from tumoral or other forms of hyperinsulinemic hy-
poglycemia, which includes hypoglycemia caused by
surreptitious insulin administration (3). Altered kinetics
of insulin clearance in the presence of antibody binding
also commonly skews insulin/C-peptide molar ratios
upward, sometimes dramatically so, as insulin clearance
is delayed while C-peptide clearance is unaffected. As
insulin/C-peptide molar ratios are often used to dis-
criminate exogenous from endogenous hyperinsulinemic
hypoglycemia (4), this raises the risk that maleficent
insulin use may be erroneously diagnosed, with po-
tentially decisive implications for criminal and child
custody proceedings.
Anti–insulin antibody (IA) assays are not standard-
ized and yield variable, qualitative, or semiquantitative
results (5); moreover, detection of IA does not prove the
presence of circulating insulin-antibody complexes (6).
Methods currently used to confirm hormone-antibody
complexes include precipitation with polyethylene
glycol (PEG), which is not specific (7), and gel filtration
chromatography (GFC), which may be used in con-
junction with ex vivo addition of insulin to enhance
sensitivity (6). Mass spectrometry (MS) methods now
offer quantification of insulin (8) that is more robust in
the face of antihormone antibody interference than
immunoassay (9).
Effective use of different immunosuppressive reg-
imens in IAS has been described, including prednis-
olone (10), hydrocortisone (11), azathioprine (12),
cyclophosphamide (13), mycophenolate mofetil (MMF)
(14, 15), rituximab (16), and plasmapheresis (17, 18), but
no consensus exists about optimal therapy. We now ex-
tend experience by presenting clinical and biochemical
characteristics of six patients with varying presentations of
IAS and responses to immunosuppression.
Materials and Methods
Patients and blood sampling
Studies were performed in accordance with the Decla-
ration of Helsinki (2000). Six exogenous insulin-naive
patients presenting with hyperinsulinemic hypoglycemia
and a high insulin/C-peptide ratio were evaluated by the
UK Severe Insulin Resistance Supraregional Assay Ser-
vice, Cambridge University Hospitals NHS Foundation
Trust, Cambridge.
Immunoassays and insulin
immunocomplex detection
Blood was collected on ice and plasma/serum rapidly sep-
arated and frozen at280°C. Plasma insulin and C-peptide were
measured using immunoassay platforms approved for clinical
use. PEG precipitation studies were performed as previously
published (6), with analyte recovery taken to be the PEG super-
natant insulin concentration expressed as a percentage of insulin
measured in matched saline-diluted samples. GFC was performed
as previously described (6).
Anti-insulin IgG was determined using an in-house hu-
man insulin–specific ImmunoCAP ELISA. IA was also de-
termined using a competitive IA RIA (19). In brief, 5 mL
serum, neat or diluted with IA-negative serum, was in-
cubated with A14-125I-labeled human insulin 6 unlabeled
synthetic human insulin at 40 mmol/L. 125I-IA complexes
were precipitated using glycine-blocked protein A Sepharose
(PAS), ethanolamine-blocked protein G Sepharose (PGS)
(20), and/or IgA agarose.
IA affinity was assessed in neat and diluted serum (21, 22),
with immune complexes precipitated using a 50:50 mixture of
PAS and PGS to include all possible IA-reactive IgG antibodies.
IC50 and Kd (mol/L) were calculated by nonlinear regres-
sion analysis using a one-site model (22) (R2 values of 0.88
to 0.99), assuming equal antibody binding by labeled and
unlabeled insulin.
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Immunosubtraction using anti–human
immunoglobulin-agarose
Synthetic human insulin, diluted in 5% BSA, was added to
plasma before 24-hour incubation at 24°C. Agarose-conjugated
anti-immunoglobulin (anti–human IgA, anti–human IgM, and
anti–human IgG) was washed thrice with 0.9% saline and
stored at 4°C. Agarose conjugates were added to plasma
at ratios based on in-house data (volume ratios of agarose-
antibody/plasma were 5:1 for anti-IgA, 29:20 for anti-IgM,
and 32:3 for anti-IgG). IgA antibody-agarose experiments
for patient 6 were performed in triplicate. Samples were
mixed for 60 minutes prior to centrifugation at 13,200g for
15 minutes. To overcome sampling error due to increased
sample viscosity, agarose supernatant was diluted in saline
prior to analysis. Insulin recovery was calculated as per-
centage insulin recovery in agarose supernatant of dilution-
matched plasma.
Quantitative mass-spectrometric analysis of insulin
and C-peptide
Pooled human plasma was fortified with insulin lispro and
C-peptide to generate concentrations of 8610 pmol/L to
17 pmol/L and 16,548 pmol/L to 33 pmol/L, respectively. Then,
250 mL of each sample of known peptide concentration,
available patient plasma, and unfortified pooled plasma was
transferred to different wells of a 2-mL 96-well plate. Five
patient and 34 control samples were extracted using a combi-
nation of acetonitrile precipitation and solid-phase extraction–
liquid chromatography (23) along with quality control samples
and analyzed with two separately extracted sets of calibration
samples. MS data were acquired fromm/z 700 to 1600, with a
resolution of 70,000 and an automatic gain control target of
3e6 ions. Insulin and C-peptide calibration curves were gen-
erated usingm/z values for the [M+5H]5+ charge states relating
to the monoisotopic (1161.7362) and multiple 13C isotopes of
human insulin and for the [M+3H]3+ charge state of C-peptide
(1007.1783). Calibration curves for insulin and C-peptide
gave a linear fit with R2 values of 0.995 and 0.994, respec-
tively, after correcting for endogenous analyte, and calibration
standards and quality control samples were all within 625%
of expected values. Regression between immunoassay and MS
control plasma values was linear for insulin (0.8727x 2
27.025;R2 = 0.974) and C-peptide (1.317x2 56.86;R2 = 0.997).
Results
A summary of the clinical characteristics of patients
studied and the investigations undertaken on initial
presentation is given in Table 1. Case histories follow.
Patient 1 presented after 20 months of shakiness,
sweating, pallor, and confusion, generally 1 to 2 hours
postprandially, which were alleviated by carbohydrate
ingestion. She had concurrently gained 7 kg in weight.
On emergency admission, plasma glucose concentration
was 30 mg/dL (1.7 mmol/L) [normal range (NR), 72 to
110 mg/dL], with concomitantly inappropriate plasma
immunoassay insulin and C-peptide concentrations of
267 pmol/L (NR,60) and 899 pmol/L (NR 174 to 960),
respectively, and amolar ratio of insulin/C-peptide of 0.30
(NR 0.03 to 0.25) (24, 25). A 72-hour fast and mixed-
meal tolerance test failed to solicit hypoglycemia, but a
75-g oral glucose tolerance test (OGTT) produced a
glucose nadir of 39 mg/dL (2.2 mmol/L) [Fig. 1(a)] at
240 minutes. A continuous glucose monitoring system
(CGMS) demonstrated labile glycemia, including late
postprandial hypoglycemia [Fig. 1(b)]. IAs were grossly
elevated at 722.4 U/mL (NR ,0.4) (RiaRSR IAA,
Cardiff, UK).
Gross hyperinsulinemia was confirmed using MS
(Table 2). Low insulin recovery following PEG pre-
cipitation using an immunoassay suggested IA. GFCwith
and without addition of exogenous human insulin
showed predominantly high molecular weight (HMW)
insulin immunoreactivity, confirming IAS (6). IAs were
positive by ELISA and RIA, the latter indicating a high
insulin-binding capacity. Competitive insulin-binding
studies (Fig. 2) suggested a subnanomolar dissociation
constant (analyzed at 10-fold serum dilution, with a two-
site model offering the best fit, with both sites binding
with high affinity).
Two 1-g intravenous methylprednisolone doses were
given 1 day apart monthly for 4 months, but symptoms
continued over the ensuing 2 years, with hypoglycemia
remaining demonstrable onOGTT andCGMS. Rituximab
(750 mg/m2 3 2) was administered, reducing glycemic
lability [Fig. 1(c)], with only two capillary blood glucose
(CBG) readings ,55 mg/dL (,3.1 mmol/L) recorded over
9 months following rituximab. At this stage, IA concen-
tration had decreased to 153 U/mL (NR ,0.4, RiaRSR
IAA), and fasting plasma insulin and C-peptide concen-
trations by immunoassay were 173 pmol/L (NR,60) and
500 pmol/L (NR 174 to 960), respectively.
Patient 2 presented with fasting symptoms of hy-
poglycemia, including syncope. She became hypogly-
cemic after 10 hours of fasting with a venous plasma
glucose of 34mg/dL (1.9 mmol/L) and concomitant plasma
insulin immunoassay concentration of 68,123 pmol/L,
C-peptide of 3690 pmol/L, and insulin/C-peptide
molar ratio of 18 (NR 0.03 to 0.25). Gross hyper-
insulinemia was confirmed by immunoassay (Table 2),
and low insulin recovery following PEG precipitation
suggested IA. GFC of plasma showed HMW insulin
immunoreactivity consistent with insulin-binding an-
tibodies, confirming IAS [Fig. 3(a)]. IAs were positive
by ELISA and RIA, the latter result consistent with
GFC findings of a very high insulin-binding capacity.
Competitive insulin-binding studies (Fig. 2) suggested a
nanomolar dissociation constant (analyzed at 10- and
50-fold dilution).
Initial diazoxide treatment was ineffective and caused
neutropenia, leading to discontinuation. Prednisolone
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30 mg daily was begun with addition ofMMF 1.5 g daily
after IAS confirmation. Hypoglycemia resolved over
the subsequent 4 weeks, with anti-insulin IgG falling to
5 mg/L, plasma insulin to 322 pmol/L, and C-peptide to
1210 pmol/L, although insulin recovery after PEG pre-
cipitation increased only modestly to 17%. Following
treatment, GFC demonstrated a reduction of HMW in-
sulin [Fig. 3(b)]. The patient remained euglycemic on
maintenance MMF for 12 months before discontinuing
immunosuppressive therapywith no evidence of recurrence
during the 12 months of follow-up to date.
Patient 3 presented with 2 years of recurrent anx-
iety, confusion, perioral paraesthesias, and generalized
diaphoresis on fasting. Typically, she would wake
during the night with feelings of terror and agitation.
These symptoms would swiftly resolve following
carbohydrate ingestion. Emergency medical atten-
dants had recorded CBG readings of 36 and 43 mg/dL
(2.0 and 2.4 mmol/L). During inpatient supervised
fasting, symptomatic hypoglycemia was recorded at
4 hours with a venous plasma glucose of 39 mg/dL
(2.2 mmol/L) and paired immunoassay plasma insulin
and C-peptide concentrations of 17,800 and 409 pmol/L,
respectively, with an insulin to C-peptide molar ratio of
44 (NR 0.03 to 0.25).
Hyperinsulinemia was confirmed using MS (Table 2).
Insulin measurement by immunoassay underestimated
total insulin in neat plasma and was nonlinear to dilution,
with low insulin recovery following PEG precipitation, all
suggesting IA. GFC showed predominantly HMW insu-
lin immunoreactivity, confirming the diagnosis of IAS
[Fig. 3(c)]. IAs were positive by ELISA and RIA, the latter
result consistent with GFC findings of a very high insulin-
binding capacity. Competitive insulin-binding studies
(Fig. 2) suggested a subnanomolar dissociation constant
(analyzed at hundred-fold serum dilution).
Initial diazoxide treatment was ineffective and was
discontinued. Prednisolone 60 mg daily, later changed
to dexamethasone 8 mg twice daily, was commenced
after IAS confirmation, with MMF twice daily later
added. CGMS demonstrated both hyperglycemia and
hypoglycemia [Fig. 1(d)]. Following nausea and raised
serum transaminases, MMF was replaced by azathi-
oprine 50 mg twice daily. High-dose steroid treatment
of hypoglycemia produced Cushing syndrome, in-
cluding agitated depression and avascular necrosis of
the hip. Rituximab (1 g 3 2) was administered and
dexamethasone weaned to 1 mg daily, but no evidence
of depletion of the pathogenic antibody [Fig. 4(a)] or
glycemic improvement was seen. Plasma exchange
(thrice weekly 3 8), in contrast, led to resolution of
hypoglycemia, disappearance of serum IA, improve-
ment in insulin immunoassay linearity [Fig. 4(b)], and
an increase in insulin recovery after PEG precipita-
tion. Although transient, this proved the efficacy of
immunodepletion, and plasma exchange followed by a
course of rituximab (750 mg/m2 3 4) was adminis-
tered. Despite amelioration of hypoglycemia, euglycemia
was not achieved, leading to further plasma exchange
and administration of rituximab (750 mg/m2 3 4), for
recrudescent hypoglycemia 6 months later. After a
further 6 months, the patient was taking azathioprine
Table 1. Clinical Characteristics and Initial Investigation of Patients Studied
Patient Age, y Sex Ethnicity BMI, kg/m2
Preexisting
Diagnoses Medications
1 56 Female Caucasian 26.2 Autoimmune hypothyroidism None
Asthma
Factor XI deficiency
2 52 Female Thai 35.0 None None
3 28 Female Caucasian 25.1 None None
4 76 Male Caucasian 29.5 Type 2 diabetes, ischemic
heart disease, parotid
pleomorphic adenoma,
glaucoma
Spironolactone, furosemide,
losartan, aspirin, bisoprolol,
atorvastatin, omeprazole,
fluoxetine
5 89 Female Caucasian 19.4 Small B-cell lymphoma Furosemide, fexofenadine,
ferrous fumarate
6 50 Male Caucasian 22.3 None None
(Continued)
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but no glucocorticoid. She no longer had fasting hy-
poglycemia but had persistent reactive hypoglycemia,
managed with dietetic support in combination with
acarbose (a-glucosidase inhibitor) to limit postprandial
insulin secretion.
Patient 4 presented with 9 months of episodic di-
aphoresis, headache, hunger, and confusion, attributed
to spontaneous hypoglycemia. Three days after initial
consultation, he had a myocardial infarction and coro-
nary artery bypass surgery. Initial plasma immunoassay
insulin concentration was 1732 pmol/L, and C-peptide
was 794 pmol/L during spontaneous hypoglycemia. Over
two 72-hour fasts, a blood glucose nadir of 45 mg/dL
(2.5 mmol/L) was recorded. Mixed-meal tolerance test
revealed early postchallenge hyperglycemia, with a peak
concentration of 232 mg/dL (12.9 mmol/L) and a late
glucose nadir of 29mg/dL (1.6mmol/L) [Fig. 1(e)]. Plasma
immunoassay insulin was concomitantly .6945 pmol/L
(C-peptide not measured). Glycemic lability was con-
firmed by CGMS [Fig. 1(f)].
Gross hyperinsulinemia was confirmed using MS
(Table 2). Insulin measurement by immunoassay under-
estimated total insulin in neat plasma and was nonlinear
to dilution, with very low insulin recovery following
PEG precipitation, suggesting IA. GFC showed predom-
inantly HMW insulin immunoreactivity, confirming IAS
[Fig. 3(d)]. IAs were strongly positive by ELISA but
equivocal by RIA, the former result consistent with GFC
findings of a high insulin-binding capacity. Unlike the
low levels of RIA binding with protein A immuno-
precipitation (Table 2), high levels were demonstrable
with protein G that could be explained by insulin bind-
ing due to IgG3. Competitive insulin-binding studies
(Fig. 2) (analyzed in neat serum) suggested a micromolar
dissociation constant.
Diazoxide (50 mg thrice daily) reduced the frequency
and severity of hypoglycemia, but after 6 months,
lanreotide 60 mg subcutaneously was added monthly as
hypoglycemia continued to compromise quality of life.
Lanreotide controlled hypoglycemia but caused gastro-
intestinal side effects, leading to its withdrawal. Acarbose
was not tolerated. Diazoxidewas continued at an increased
dose (100 mg thrice daily) for 3 years with concomitant
diuretics to manage edema. HbA1c on diazoxide remained
around 55 mmol/mol (NR 20 to 42). Immunomodulatory
therapy was declined but remains under consideration.
Patient 5 presented with recurrent falls associated with
cognitive decline. Borderline low CBG concentrations at
50 mg/dL (2.8 mmol/L), as well as concentrations as high
as 248 mg/dL (13.8 mmol/L) consistent with diabetes
mellitus, were noted during admission, but no glycopenic
symptoms were apparent. Plasma immunoassay insulin
concentration, at a time when blood glucose concen-
tration was 37 mg/dL (2.1 mmol/L), was 1024 pmol/L
with a concomitant C-peptide of 679 pmol/L and insulin
to C-peptide molar ratio of 1.51 (NR 0.03 to 0.25). Gross
hyperinsulinemia was confirmed using MS (Table 2).
Insulin measurement by immunoassay underestimated
Table 1. Clinical Characteristics and Initial Investigation of Patients Studied (Continued)
Presentation
Investigations With
Abnormal Resultsa
Investigations With
Normal Resultsa Negative Imaging
Postprandial hypoglycemia OGTT nadir 39 mg/dL
(2.2 mmol/L)
HbA1c CT abdomen
CGMS 72-h fast nadir 59 mg/dL
(3.3 mmol/L)
MRI abdomen
MMTT Endoscopic US
SU screen
a-Islet, a-GAD65, a-IA2, a-INSR
autoantibodies
Fasting hypoglycemia SU screen a-INSR autoantibodies 68Ga-DOTATATE PET/CT
Fasting hypoglycemia HbA1c SU screen 68Ga-DOTATATE PET/CT
Postprandial/ nocturnal
hypoglycemia
MMTT nadir 29 mg/dL
(1.6 mmol/L)
72-h fast nadir 45 mg/dL
(2.5 mmol/L)
MRI abdomen
CGMS Endoscopic US
Octreotide SPECT
18F-Deoxyglucose-PET
Low-capillary blood
glucose readings
Short Synacthen test nil
Postprandial hypoglycemia OGTT nadir 26 mg/dL
(1.4 mmol/L)
72-h fast nadir 72 mg/dL
(4.0 mmol/L)
CT abdomen
SU screen
Abbreviations: BMI, bodymass index; GAD, glutamic acid decarboxylase; IA2, islet antigen-2;MMTT, mixedmeal tolerance test; OGTT, oral glucose tolerance test;
PET, positron emission tomography; SPECT, single-photon emission computerized tomography; SU, sulfonylurea; US, ultrasound; a-INSR, anti–insulin receptor.
aHypoglycemia with inappropriately elevated plasma insulin was an inclusion criterion for this study and was excluded from the table.
doi: 10.1210/jc.2018-00972 https://academic.oup.com/jcem 3849
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/10/3845/5061434 by U
niversity of Bristol Library user on 22 O
ctober 2018
total insulin in neat plasma and was nonlinear to di-
lution, with very low insulin recovery following PEG
precipitation, suggesting IA. GFC showed HMW insulin
immunoreactivity, confirming IAS. IAs were positive by
ELISA and RIA, and competitive insulin-binding studies
(Fig. 2) (analyzed at 10-fold serum dilution) suggested
a submicromolar dissociation constant. Further in-
vestigation and treatment were declined, and the patient
was discharged to residential care with a CBG meter and
advice to avoid fasting. Four months later, she was ad-
mitted to the hospital with reduced consciousness and a
CBG reading of 23 mg/dL (1.3 mmol/L). Blood glucose
normalized with intravenous glucose. Prednisolone 10 mg
daily was commenced and the patient was discharged
with advice for regular blood glucose monitoring, and
glucose gel was provided. She has since died.
Patient 6 presented with two episodes of loss of
consciousness due to hypoglycemia. On both occasions,
low CBG was detected, and he was admitted to the
hospital for emergency treatment. He had no family
history of diabetes or hypoglycemia. Two 72-hour fasts
failed to provoke hypoglycemia, with a glucose nadir
during the first fast of 72 mg/dL (4.0 mmol/L). In con-
trast, prolonged 75-g OGTT produced a glucose nadir
Figure 1. Variable patterns of dysglycemia of patients studied. (a) Venous plasma glucose concentrations during a 75-g OGTT at presentation of
patient 1; s denotes glucose measurements following glucose rescue. The glucose nadir was 39 mg/dL (2.2 mmol/L). (b) Demonstration of labile
glycemia in patient 1 at presentation by CGMS. (c) Demonstration of normoglycemia in patient 1 following immunomodulation therapy. (d)
Demonstration of labile glycemia in patient 3 concomitant with glucocorticoid therapy. (e) Demonstration of reactive hypoglycemia in patient 4
at presentation by mixed-meal tolerance test. The peak glucose concentration was 232 mg/dL (12.9 mmol/L) with glucose nadir at 300 minutes
of 29 mg/dL (1.6 mmol/L). (f) Demonstration of reactive and nocturnal hypoglycemia in patient 4 at presentation by CGMS. (g) Demonstration of
reactive hypoglycemia in patient 6 at presentation by 75-g OGTT. The glucose nadir was 26 mg/dL (1.4 mmol/L). (h) Demonstration of labile
glycemia in patient 6 at presentation by CGMS.
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of 26 mg/dL (1.4 mmol/L) [Fig. 1(g)] with a corre-
sponding immunoassay insulin of 1285 pmol/L, C-peptide
of 1006 pmol/L, and insulin to C-peptide ratio of 1.28
(NR 0.03 to 0.25) at 180 minutes after the glucose load.
This led to loss of consciousness, which was rescued with
intravenous glucose. IAS was suspected, and prednis-
olone 60 mg with diazoxide 300 mg daily was com-
menced. IAs were, however, within reference limits using
two RIAs.
Gross hyperinsulinemia was confirmed using MS
(Table 2). Insulin measurement using immunoassay
underestimated total insulin in neat plasma and was
nonlinear to dilution, with low insulin recovery following
PEG precipitation, suggesting IA. GFC studies with and
without preincubation of plasma with exogenous human
insulin showed HMW insulin immunoreactivity consis-
tent with insulin-binding antibodies, confirming the di-
agnosis of IAS [Fig. 3(e)]. IAs were equivocal by ELISA
and negative by RIA, which was inconsistent with GFC
findings of a high insulin-binding capacity. To identify
the class of the putative IA, immunosubtraction studies
were performed using antibody class-specific antibodies
conjugated to agarose. Patient 6 plasma was compared
with control plasma with insulin-binding IgG and three
plasma samples with no evidence of insulin autoim-
munity, all matched for insulin concentration. To in-
crease the sensitivity of the method to detect IA, plasma
was incubated with synthetic human insulin to drive the
binding equilibrium in favor of bound insulin. Plasma
insulin recovery was close to 100% in all cases except
for those with anti-insulin IgG subtracted for IgG and
patient 6 subtracted for IgA. In both cases, recovery fell
to around 50% to 60%, indicating the presence of anti-
insulin IgA in patient 6. In keeping with this, no in-
creased precipitation of radiolabel was seen using either
protein G or protein A, but demonstrably increased
precipitation was seen with anti-IgA agarose. The
baseline PAS/PGS radioligand binding was too low
(analyzed in neat serum) to allow reliable calculation of
binding affinity.
Prednisolone was reduced to 40 mg daily, and no
further symptomatic hypoglycemia was recorded. Four
months following diagnosis, during prednisolone treat-
ment, blood tests confirmed the continued presence of
insulin-binding antibodies. CGMS confirmed labile gly-
cemia, with matutinal hyperglycemia and postprandial
hyperglycemia [Fig. 1(h)] leading to immunodepletion
therapy being considered.
Quantitative liquid chromatography–MS insulin and
C-peptide results
Individual results are shown in Table 2. There was
insufficient plasma from patient 2 for analysis. Molar
ratios of IAS insulin/C-peptide ranged from 3.7 to 8.4,
and for 34 control plasma samples, they ranged from 0.2
to 1.5, with one outlier of 0.02.
Discussion
IAS has been reported most widely in Japan (1), and
despite numerous but scattered reports elsewhere and
frequent airing of the diagnostic possibility in forensic
investigation of suspected insulin poisoning, there is
relatively little awareness of the condition in the
Western Hemisphere among endocrinologists. IAS
most often presents with hypoglycemia, which may be
postprandial, postabsorptive, or fasting. In this series,
the presenting symptoms ranged from daytime loss of
consciousness to modest symptoms only after over-
night fasting. Patients 1, 4, and 6 displayed reactive
hypoglycemia on dynamic testing, whereas in patients
2 and 3, hypoglycemia was provoked by fasting.
Prolonged fasting of patients 1, 4, and 6 did not result
in hypoglycemia using thresholds aimed at exclud-
ing insulinoma, as in some published cases of IAS
(16, 26, 27). Four of six patients underwent imaging
using modalities including MRI, endoscopic ultraso-
nography, and positron emission tomography/single-
photon emission computerized tomography before
IAS was diagnosed. Suggestive biochemical evidence
for IAS existed in each case, and some imaging may have
been avoided with earlier access to definitive testing.
In this series, the first clue to IAS came from high
insulin concentrations and insulin/C-peptide molar
ratios in samples drawn during hypoglycemia. Im-
munoassay results were shown to be nonlinear to di-
lution at presentation (linearity improving following
plasma exchange) and to underestimate MS-detected
insulin in neat plasma, consistent with assay inter-
ference due to the IA competing with the immunoas-
say antibodies for insulin-binding sites (6). Consistent
with previous observations (28–31), immunoassay
C-peptide concentrations, in the five patients in whom
they were measured, were reported at hundreds to
thousands of picomoles per liter, concurrent with hy-
poglycemia. Immunoassay C-peptide concentrations in
patients 1, 3, 4, and 6 conversely overestimated MS
C-peptide more than may be expected from assay bias
alone (32), possibly due to cross-reacting insulin pre-
cursors not detected by the MS method. As MS methods
are not susceptible to antibody interference, they are
more likely to return a correct value for total insulin
concentration in IAS and thus increased confidence in
the diagnosis.
IAs are a sine qua non of IAS (33), but assay sen-
sitivity and specificity in the diagnosis of IAS have not
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been established. Indeed, IAs were first described in
patients receiving exogenous insulin (34, 35) with such
frequency that in early literature, the presence of such
antibodies in hypoglycemic ostensibly insulin-naive
patients was regarded as nearly diagnostic of sur-
reptitious insulin administration (36). They are now
well established in the repertoire of autoantibodies
used to identify type 1 diabetes (37) and to stratify
nondiabetic people according to the risk of autoim-
mune diabetes (38, 39). They may also be detected in
healthy blood donors or patients with unrelated
autoimmune disorders (40–42). Different diagnostic
laboratories use different methods; these are non-
standardized, and assay concordance remains poor (5,
43) despite longstanding attempts at harmonization
(44). In all patients, recovery of immunoreactive in-
sulin after PEG precipitation was low and GFC con-
firmed HMW insulin-containing complexes, but not
all patients had elevated IA on initial testing. In this
study, ELISA and RIA moreover produced differ-
ent rankings of the magnitude of the results, possibly
due to differential effects of high endogenous insu-
lin concentrations. Antibody characteristics will also
contribute to assay variability: for patient 4, the
ELISA/RIA discrepancy may be attributable to un-
derrepresentation of IgG3 in immunoglobulins cap-
tured by protein A prior to RIA. More strikingly, in
patient 6, equivocal or negative antibody levels were
determined using four different IA assays, despite
convincing GFC evidence of insulin-antibody complexes.
Anti-insulin IgA was ultimately demonstrated by immu-
nosubtraction, explaining the discrepancy. Only;70% of
IgA is removed using PEG precipitation (in-house data),
explaining the relatively modest suppression of recovery
after PEG precipitation in this case and raising the
possibility that PEG precipitation may offer false
reassurance in the presence of IgA IA. The use of
alternative immunoprecipitation methods may in-
crease the sensitivity of these tests but offer diminishing
returns and increase complexity and cost. For example,
further studies using anti-IgA showed patient 5 also
to possess notable IgA IA binding of insulin. Un-
fortunately, there is no failsafe method for immuno-
subtraction of immunoglobulin subclasses. It is tempting
to speculate that patients 2 and 3 exhibited hypo-
glycemia principally during fasting due to the high
affinity and very high capacity of their IA, but anti-
body capacity and affinity did not appear to correlate
with physiological abnormality across the whole
group studied.
Hypoglycemia in IAS has been reported to resolve
spontaneously in most patients within 3 months (1).
The severe hypoglycemia seen in this series, sustained
over months or years, allied to other reports, dem-
onstrates that this is not always true, however. As IAS
is antibody mediated, targeting of pathogenic anti-
bodies is rational. In keeping with this, diazoxide,
which targets insulin secretion, showed modest or no
benefit. Four patients in this series to date were treated
with immunomodulatory therapies. Patient 1 was
treated with glucocorticoids alone over .4 months,
but intermittent hypoglycemia persisted and so ther-
apy with rituximab was used. Patient 6 also failed
to experience improvement of glycemic lability, and
immunodepletion therapy is being considered. Pa-
tients 2 and 3 were both initially treated with gluco-
corticoids and MMF, but although patient 2 appears
to have gone into remission relatively quickly, patient
3 continued to experience severe hypoglycemia, de-
spite high-dose glucocorticoids (which caused severe
side effects). Ultimately, it was necessary to combine
plasma exchange with rituximab therapy. Collec-
tively, this demonstrates that therapeutic responses
are variable.
Table 2. Biochemical Evaluation of Nonfasting Plasma in a Single Specialized Center
Patient No.
MS Insulin,
pmol/L
Immunoassay Insulin,
pmol/L (<60)
Insulin Recovery After
PEG Precipitation, % (>102) GFC of Insulin
Anti-Insulin IgG,
mg/L (0–5)a
Dilution Ratio
(Plasma/Diluent)
1:0 1:4
1 5278 .3000 7020 8 HMW insulin present 16
2 — .3000 11,585 6 HMW insulin present 38
3 1583 782 4601 9 HMW insulin present 11
4 2912 1340 3912 11 HMW insulin present .200
5 6589 2781 7805 3 HMW insulin present 89
6 4012 2906 5630 65 HMW insulin present 5
(Continued)
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In summary, IAS should be considered in cases
of spontaneous hypoglycemia with a high insulin/
C-peptide molar ratio. Measurement of IA is an ap-
propriate screening step, but although the IA assays
used in this series detected antibodies in five patients,
they were equivocal or negative in patient 6, illustrat-
ing that IA results are assay dependent (5). Moreover,
detection of IA alone is not specific for actionable anti-
bodies (6), meaning that further measures to confirm
plasma insulin-antibody complexes are required for
diagnosis. MS-based methods promise to increase di-
agnostic confidence as they are unaffected by antibody-
based assay interference. Immunodepletion is warranted
in severely affected patients. Our series demonstrates
that therapeutic responses vary, and so a customized
and flexible approach to depleting pathogenic antibodies
is required. More standardized approaches to IAS
diagnosis will facilitate the systematic therapeutic
studies required.
Figure 3. Demonstration of insulin-antibody complexes using
GFC. Results of insulin assay after GFC of nonfasting plasma.
Elution volumes of immunoglobulin (Ig), albumin (Alb), and
monomeric insulin (mIns) are shown. Results are shown for
patient 2 at (a) presentation (pretherapy) and (b) with and
without preincubation of plasma with exogenous insulin
posttherapy, as well as with and without preincubation of
plasma with exogenous insulin at presentation for (c) patient 3,
(d) patient 4, and (e) patient 6.
Figure 2. Displacement curves for serum samples from patients 1
to 5 at various dilutions in antibody-negative serum following
competitive displacement with unlabeled human insulin. Although
identified as low affinity (4.1 3 1027 mol/L), patient 6 plasma was
considered unreliable because baseline levels of insulin binding
were very low. Serum was diluted as follows: patient 1, 10-fold;
patient 2, 50-fold; patient 3, 100-fold; patient 4, neat; patient
5, 10-fold.
Table 2. Biochemical Evaluation of Nonfasting Plasma in a Single Specialized Center (Continued)
IA, cIA Units (<0.2) Kd, mol/L
MS C-peptide,
pmol/L
Immunoassay C-peptide,
pmol/L (174–960)
MS Insulin/C-peptide
Molar Ratio (0.2–1.5)
Immunoassay Insulin/
C-Peptide Molar Ratio
(0.03–0.25)
2408 3.42 3 10210 1428 3750 3.7 1.9
8738 1.16 3 1029 — 5580 — 2.1
.10,000 4.68 3 10210 215 2380 7.4 0.3
4.0 6.55 3 1026 348 1190 8.4 1.1
300 8.55 3 1027 880 3110 7.5 0.9
0.1 — 750 3280 5.4 0.9
Abbreviations: cIA, competitive insulin antibody; Kd, dissociation constant.
aThe reference range used for the anti-insulin IgG assay was provided by a reference laboratory using the samemethod (Sheffield Protein Reference Unit,
Sheffield, UK). Testing 28 of the 34 control samples used in the quantitativemass-spectrometric analysis of insulin and C-peptide yielded a 75th percentile
insulin antibody concentration of 4.8 mg/L.
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